Acquired by Codex Opportunity to re-engage customers or partners connected to Eton Bioscience, now under Codex DNA ownership, with cross-sell of Codex portfolio including DNA synthesis, sequencing, and related synthetic biology services.

Small-to-Mid Biotech Focus Target universities, startups, and mid-sized biotech firms in need of scalable molecular biology tools and services, leveraging Eton's established capabilities in DNA sequencing, oligo and gene synthesis, and protein/antibody solutions.

Growing Outsourcing Needs Capitalize on the demand for cost-effective, high-quality molecular biology workflows by offering full-service outsourcing, rapid turnaround, and flexible engagement models to research groups with limited in-house capacity.

San Diego Hub Leverage proximity to the San Diego biotech cluster to pursue regional collaborations, academic grants, and early-access programs for new workflows, positioning as a local partner for university labs and start-ups.

Revenue Range Insight With reported revenue in the $10M–$25M range and a lean employee base, present scalable pricing, pilot programs, and tiered services to convert mid-market opportunities into longer-term contracts, while aligning with Codex DNA’s product lines.